CGON
CG Oncology, Inc. Common stockKey Statistics
About CG Oncology, Inc. Common stock
CG Oncology, Inc. is a clinical-stage biotechnology company dedicated to developing groundbreaking cancer therapies, with its lead product, CG0070, an innovative oncolytic virus therapy targeting non-muscle invasive bladder cancer. The company is poised to address significant unmet medical needs in oncology, underscoring its potential to improve patient outcomes and reshape treatment approaches. As CG Oncology advances through clinical trials and critical regulatory milestones, it leverages its proprietary technology platform to distinguish itself in the competitive oncology sector. This strategic emphasis on pioneering therapeutic options presents an attractive opportunity for institutional investors interested in advancements that could significantly impact cancer care.
Fundamentals
| Revenue (TTM) | $4.04M |
| Gross Profit (TTM) | $-117.25M |
| EBITDA | $-189.33M |
| Operating Margin | -2097.00% |
| Return on Equity | -21.70% |
| Return on Assets | -15.40% |
| Revenue/Share (TTM) | $0.05 |
| Book Value | $9.33 |
| Price-to-Book | 7.70 |
| Price-to-Sales (TTM) | 1455.65 |
| EV/Revenue | 1253.02 |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 409.20% |
| Shares Outstanding | $88.01M |
| Float | $69.04M |
| % Insiders | 0.65% |
| % Institutions | 110.45% |
Historical Volatility
Volatility is currently expanding